The UK and US have hammered out a significant commercial pact that will ensure no levies on UK pharmaceutical products entering the American market.
The Terms of the Accord
As part of the deal, the UK has agreed to raise funding on pharmaceuticals through the National Health Service (NHS). This pledge ensures that import taxes on these vital exports will stay at zero for a duration of three years.
This agreement comes after earlier threats to dramatically increase import taxes on patented drug imports, with potential rates mentioned up to one hundred percent.
"This arrangement between the UK reinforces the global environment for cutting-edge drugs and brings much-needed balance to U.S.–U.K. medicine commerce," a release declared.
Commercial Impact
Pharmaceuticals constitute one of the UK's biggest goods shipped to the America, which is easily the primary market for major UK drugmakers.
Statistics show that in the one-year period leading up to last September, the UK exported medicines worth £11.1bn to the US. This amount made up nearly one-fifth of British export trade in that period.
"This deal safeguards employment, stimulates capital expenditure and facilitates the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Specific NHS Changes
The pact entails several specific commitments from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to double overall NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to prevent overspending will be limited at 15%. In the past, repayments exceeded 20%.
Broader Context
This agreement comes amid a protracted row between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
These tensions were exacerbated by arguments that US customers were charged several times more for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been directed toward US facilities.
One official acknowledged that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had declined as a share of its resources over the previous ten-year period.
